[The antiemetic activity of buspirone].
The low activity of conventional antiemetic drugs by chemotherapy of oncological diseases has determined the necessity to evaluate the activity rate of 5-hydroxytryptamine receptors' agonists. Experimental data show, that buspirone exceeds significantly all the used antiemetics what allows to expect its high activity in the clinic.